Ivabradine approved by NICE for heart failure

The National Institute for Health and Clinical Excellence has accepted ivabradine (Procoralan) for use in certain patients with chronic heart failure.

Chronic heart failure affects about 900,000 people in the UK and is often caused by coronary artery disease, for example following an acute MI  | SCIENCE PHOTO LIBRARY
Chronic heart failure affects about 900,000 people in the UK and is often caused by coronary artery disease, for example following an acute MI | SCIENCE PHOTO LIBRARY

The sinus node If inhibitor is recommended as an option for prescribing on the NHS to patients:

  • with NHYA class II–IV stable chronic heart failure with systolic dysfunction and
  • who are in sinus rhythm with a heart rate ≥75 bpm and
  • who are also receiving standard therapy, including a beta-blocker, an ACE inhibitor and an aldosterone antagonist, or when a beta-blocker is contraindicated or not tolerated, and
  • who have a reduced left ventricular ejection fraction (LVEF) ≤35%.

May be managed in primary care following initiation

Patients should only be prescribed ivabradine following 4 weeks of optimised standard therapy and under the supervision of a heart failure specialist with access to a multidisciplinary team. Subsequent dose titration and monitoring can be managed either by the same specialist or by a GP with a special interest in heart failure or a heart failure specialist nurse.

Dose adjusted according to response and heart rate

Patients should be started on 5mg twice daily with morning and evening meals. The dose is then adjusted according to response and heart rate, within range 2.5–7.5mg twice daily.

NICE guidance on ivabradine in heart failure

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.